Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IMGN853: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 18 patients showed that IV IMGN853 led to 2 partial responses and 1 case

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE